Are there clinical trials suitable for treating recurrent Lymphoma, and how can I determine if I am eligible
According to the National Cancer Institute (NCI), clinical trials are often excellent options for patients with recurrent lymphoma, as they provide access to the newest treatments and approaches that may be more effective than standard therapies.
The Leukemia & Lymphoma Society (LLS) outlines several key points about clinical trials for lymphoma:
- Different types of trials are available, including:
- New targeted therapies
- Immunotherapy approaches
- Novel drug combinations
- CAR T-cell therapy studies
- Eligibility typically depends on:
- Specific lymphoma type and subtype
- Previous treatments received
- Current health status
- Age and other medical conditions
According to NCCN Guidelines, patients should consider clinical trial participation at any point in their treatment journey, but especially in the relapsed/refractory setting where standard options may be limited.
To find and determine eligibility for specific trials:
- Visit clinicaltrials.gov (NCI-supported database)
- Consult the LLS Clinical Trial Support Center, which offers free one-on-one assistance
- Discuss options with your oncologist who can help identify appropriate trials
Important considerations:
- Always consult with your healthcare team about trial options
- Each trial has specific inclusion/exclusion criteria
- Location and travel requirements should be considered
- Some trials may require specific genetic or biomarker testing
Would you like me to provide more specific information about certain types of clinical trials or help you understand how to connect with trial resources?
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients (Lymphomas) — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 15, 2025. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients (Lymphomas) (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with clinical trials for Lymphoma patients
Have your records handy? Add them to a private case for a deeper, personalized read →
Expert Webinars on Lymphoma
More questions about Lymphoma
- What should I consider when choosing between clinical trial and standard treatment for Lymphoma
- Is recurrent Lymphoma harder to treat than the original
- What is the role of PARP inhibitors in treating Lymphoma
- What is the role of radiation therapy in treating Lymphoma
- What is the difference between phase 1, 2, and 3 trials for Lymphoma
- What does progression mean for Lymphoma and what happens next
- What should caregivers know about Lymphoma treatment
- What is oligometastatic Lymphoma and can it be cured